Pfizer Inc PFE

$29.21 +0.84 (2.96%)

Valuation

Market cap
161,870,736,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.27
Forward PE
9.57
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
39,370,500
Avg volume
34,498,504
Day's range
$28.55 – $29.49
Shares out
5,699,674,000
Stochastic %K
84%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Doozio Oct 14, 9:19 PM
$MRNA $PFE $XLE YO @MarketSurge da fook? Bill would be rolling over in his grave. 💯?? N this stream is ❤️💯. Da fook. Let’s pray 🙏
1 replies
Eagle_eye_trader Oct 14, 8:50 PM
$PFE any catalyst on this one to make it move like mRNA
0 replies
umiak1 Oct 14, 8:49 PM
$PFE “2012, Pfizer out-licensed a clinical-stage molecule called PF-04554878 to Verastem. • The Asset: This molecule was a FAK (Focal Adhesion Kinase) inhibitor, which targets cancer stem cells to prevent tumor recurrence. • The Deal: Verastem took over sole global development, renaming the drug VS-6063 (defactinib). In exchange, Pfizer received upfront cash, Verastem equity, and a stake in future milestone/royalty payouts.”
1 replies
zustrelaax Oct 14, 8:36 PM
$PFE wide open any news like mRNA should squeeze it above 35
0 replies
FreedomQuestTrader Oct 14, 8:29 PM
$PFE ended up moving exactly like we predicted 🔥
0 replies
MrPeanutEsquire Oct 14, 8:27 PM
$PFE Hey maw, were about to be on cnbc
1 replies
Quantumup Oct 14, 8:08 PM
Stifel ($IDYA Buy-$48) also said that it models global product revenue of about $1.42B by 2035 for the darovasertib + crizotinib combo in 1L HLA-A*02:01-negative mUM. $PFE $NVS REPL ESAIY AMGN AZN ABBV MRK DSNKY ZLAB
0 replies
razorsedge4343 Oct 14, 8:00 PM
$MO $PFE At least everything didn't dump today...
0 replies